From the Stanford Cardiovascular Institute, CA (T.S., J.C.W.); Department of Medicine, Division of Cardiology (T.S., J.S.W.); Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine (M.P.); and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (M.P., J.C.W.).
Circ Res. 2017 Mar 3;120(5):778-780. doi: 10.1161/CIRCRESAHA.116.310197.
Genome editing has emerged as a powerful tool in research and is entering the stage of therapeutic applications. In the cardiovascular field, its role in basic and translational research is well established. However, biological and technical barriers currently hamper the therapeutic potential of genome editing for cardiovascular diseases. This viewpoint discusses possible routes for promoting therapeutic use of genome editing in the cardiovascular system.
基因组编辑已成为研究领域中的强大工具，并正进入治疗应用阶段。在心血管领域，它在基础和转化研究中的作用已得到充分证实。然而，目前生物学和技术方面的障碍限制了基因组编辑在心血管疾病治疗中的潜力。本文观点探讨了促进基因组编辑在心血管系统中治疗用途的可能途径。
